spacer
home > pmps > winter 2017 > sizing up
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Sizing Up

The search for effective therapies for lung diseases – such as asthma and chronic obstructive pulmonary disease (COPD) – has led to a rise in the number of products that require targeted distribution to the lung for efficacy. New concepts increasingly necessitate innovative approaches and are becoming tailored to specific patient populations – the elderly or paediatrics, for example, with more limited pulmonary capacities. Many of these demand preparation and delivery beyond the performance range of more precedented technologies, like pressured metered dose or dry powder inhalers that are based on conventional lactose-blended formulations. There are also handling and product distribution challenges associated with many of the compounds and/or their target patient populations.

There is growing interest in transporting biotherapeutics to the lungs – like vaccines – that might promote enhanced antigen response in the area where the virus first enters the body. These molecules are often challenging to deliver and utilise the most established options, because they are not compatible with reducing sugars and are sensitive to attrition milling. Distributing antibiotics to the lungs in order to aid patients with compromised lung function and increased risk of infection due to poor escalatory clearance – typically those with cystic fibrosis – is also gaining traction. These therapies require the delivery of large doses, often much higher than 5mg of active pharmaceutical ingredient (API) per respiratory event, which is very limited with lactose-blend technologies.

Highly potent APIs are increasingly being used in pulmonary applications for acute inflammation as well as specialised high containment infrastructure, and protocols are needed to handle these at all stages of the product development cycle. Many firms cannot justify the investments required – especially the small to mid-sized speciality companies that hold much of the early stage development pipeline – and therefore must utilise contract development and manufacturing organisations. There are a limited number of such partners with the capability of handling these types of compounds as well as the inhalable product formulation expertise and processing infrastructure, especially with respect to commercial scale production.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Devon B DuBose is Director of Early Phase Formulation and Process Development at Capsugel’s Bend Research site. His responsibilities include leading multiple teams focused on the development of early phase drug candidates and technology transfer into Bend Research’s current Good Manufacturing Practice facility for clinical development. Devon’s technical focus during his time at Bend Research has been on spray drying formulation and process development for oral and inhalation drug products.
spacer
Devon D DuBose
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement